Who are TPF+CCRT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FLOT, CVP, chemotherapy of mFOLFOX6 or FOLFIRI, Dose dense AC followed by T + trastuzumab, TCH chemotherapy, CEV chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tpf-ccrt.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

TPF+CCRT — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TPF+CCRT (TPF+CCRT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy regimen. Area: Oncology.

phase 3 Chemotherapy regimen Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TPF+CCRT (TPF+CCRT) — Guiyang Medical University. TPF+CCRT is a chemotherapy regimen that combines docetaxel, cisplatin, and fluorouracil to target rapidly dividing cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TPF+CCRT TARGET	TPF+CCRT	Guiyang Medical University	phase 3	Chemotherapy regimen
FLOT	FLOT	European Organisation for Research and Treatment of Cancer - EORTC	marketed	Chemotherapy regimen (combination)
CVP	CVP	SCRI Development Innovations, LLC	marketed	Combination chemotherapy regimen
chemotherapy of mFOLFOX6 or FOLFIRI	chemotherapy of mFOLFOX6 or FOLFIRI	Xu jianmin	marketed	Combination chemotherapy regimen	Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin)
Dose dense AC followed by T + trastuzumab	Dose dense AC followed by T + trastuzumab	Agendia	marketed	Chemotherapy regimen with monoclonal antibody	HER2 receptor (trastuzumab component); DNA/microtubules (chemotherapy components)
TCH chemotherapy	TCH chemotherapy	Agendia	marketed	Chemotherapy regimen (combination)	HER2, microtubule, DNA
CEV chemotherapy	CEV chemotherapy	Sun Yat-sen University	marketed	Combination chemotherapy regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy regimen class)

National Research Center for Hematology, Russia · 2 drugs in this class
Asan Medical Center · 1 drug in this class
AstraZeneca · 1 drug in this class
CTI BioPharma · 1 drug in this class
Federation Francophone de Cancerologie Digestive · 1 drug in this class
Guiyang Medical University · 1 drug in this class
Japan Clinical Oncology Group · 1 drug in this class
PETHEMA Foundation · 1 drug in this class
Sixth Affiliated Hospital, Sun Yat-sen University · 1 drug in this class
Trans Tasman Radiation Oncology Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TPF+CCRT — Competitive Intelligence Brief. https://druglandscape.com/ci/tpf-ccrt. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing